Applied Therapeutics CRL a ‘major setback,’ says William Blair
William Blair says Applied Therapeutics (APLT)’ complete response letter from the FDA for govorestat for the treatment of galactosemia is “unexpected and disappointing.” Given the lack of information ...
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow.
The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.
devdiscourse1d
Black Friday Boost: Retail Stocks Rise Amid Record Consumer Spending Predictions
Chip and crypto stocks rose, while Applied Therapeutics fell sharply after FDA denial. This image is AI-generated and does ...
devdiscourse1d
U.S. Stock Markets Gear Up for Black Friday Boost
Retailers are in focus with an expected surge in shoppers, while other market movements include crypto gains and a plunge in ...
Biopharmaceutical Company's Stock Plunges 75% After FDA Rejects New Drug
Applied Therapeutics' stock plummeted 75 percent after the Food and Drug Administration (FDA) rejected approving govorestat ...
FDA Rejects Applied Therapeutics' NDA for Govorestat, Citing Flaws; Shares Plunge 76%
Applied Therapeutics ( APLT, Financials) announced that the U.S. Food and Drug Administration issued a Complete Response ...
Top Stock Movers Now: Hasbro, MicroStrategy, Super Micro Computer, and More
U.S. equities headed to Friday's early close—and the conclusion of November trading—in positive territory as the ...
Applied Therapeutics Stock Plummets After FDA Rejects Metabolic Disease Drug
Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...
RBC downgrades Applied Therapeutics as FDA rejects Govorestat, hacks price target
RBC Capital Markets downgraded Applied Therapeutics Inc (NASDAQ:APLT) stock to "sector perform" from "outperform” citing ...
Applied Therapeutics stock craters 75% on FDA setback
Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...
Regulatory Setback For Applied Therapeutics' Lead Program, FDA Highlights Deficiencies In Clinical Application
FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for ...
bovnews2d
Stock Slump or Stepping Stone? What’s Next for Applied Therapeutics (APLT) After FDA’s Latest Blow
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company focused on rare diseases, saw a significant drop in its stock price following the recent news that the U.S. Food ...